- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05469373
ESIS en DRE pediátrico
Estimulación eléctrica para la inducción de convulsiones en epilepsia pediátrica refractaria a fármacos (ESIS en DRE pediátrico).
The main reason for this research study is to gain information about how the brain makes seizures by causing seizures using very small amounts of current, or electrical stimulation. Using small amounts of current to cause seizures (or stimulate) is not new at CCHMC - it is part of routine clinical practice for some patients at some electrodes.
This study differs from routine clinical care in that all study patients will undergo electrical stimulation in all or nearly all electrode contacts. The study team is doing this because there is promising data in adult patients that stimulating comprehensively (targeting all or nearly all of the electrode contacts) helps define the seizure network. Defining the seizure network in turn helps the medical team plan surgery. So far, there is not as much published data on seizure stimulation for pediatric patients.
This research study thus has the potential both to help individual patients (by providing specific information about your seizure networks) and to help pediatric patients with epilepsy in general (by increasing our understanding of stimulated seizures in children, teenagers and young adults).
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Epilepsy affects about 1% of the population, with roughly 30% of patients with epilepsy eventually developing drug-resistant epilepsy (DRE). Increasingly, surgery is pursued for DRE, yielding seizure freedom rates of 50-70%. However, accurate deduction of the epileptogenic zone (EZ) for surgical planning can be difficult in pediatric DRE, especially in those cases of multifocal seizures, as is often seen in Tuberous Sclerosis Complex (TSC), for example. Patients with multifocal epilepsy typically require a period of pre-surgical invasive EEG monitoring to record spontaneous seizures, the gold standard for EZ deduction. Unfortunately, the invasive monitoring process may be lengthy, costly and even fail to reveal a dominant EZ.
Electrical stimulation of induced seizures (ESIS) using stereo EEG (sEEG) has been shown to be a safe and valid adjunct for EZ delineation in adults with DRE. ESIS can be implemented within 1-2 days of electrode implantation, while the patient would otherwise be passively awaiting spontaneous seizures. ESIS typically induces habitual seizures with few side effects, and there is no data to suggest that ESIS inhibits spontaneous seizures or prolongs the otherwise clinically-indicated hospital stay. Crucially, published data show that induced seizures provide information about the EZ that is both convergent with and unique from that provided by spontaneous seizures. Despite these promising reports, ESIS is not widely integrated into pediatric DRE evaluation.
The overall objective is to improve methods of EZ identification in pediatric DRE patients with complex EZs, thereby increasing the likelihood of surgical candidacy for patients and ultimately improving surgical outcomes. In this protocol, investigators hypothesize that electrical stimulation of induced seizures (ESIS) is an effective adjunct for EZ delineation in children with DRE. To test this, the study will enroll n=86 patients with DRE undergoing sEEG evaluation aged 1-30 years. Based on the CCHMC epilepsy surgery program throughput, it is anticipated that this will include approximately n=36 patients with TSC and n=50 without TSC, which will provide the opportunity to compare the utility of this technique between patients with and without TSC. Patients will undergo ESIS using published Cincinnati Children's Hospital Medical Center (CCHMC) parameters with modifications. Gray and white matter contacts will be stimulated systematically. Safety, tolerability, yield, validity and parameter space will be examined.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Participants with drug-refractory epilepsy who receive care at or are referred into the CCHMC Comprehensive Epilepsy Center will comprise the targeted study population. Specifically, those patients who undergo phase I evaluations and are subsequently recommended for phase II evaluations at CCHMC will be identified as research study candidates.
Descripción
Inclusion Criteria:
- Diagnosis of drug-refractory epilepsy (DRE)
- 1-30 years of age
- recommended to undergo stereoencephalography (sEEG) at CCHMC
Exclusion Criteria:
- <1 and >30 years of age
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_ONLY
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety -- Occurrence of generalized, convulsive and prolonged seizures
Periodo de tiempo: Phase II epilepsy surgery testing
|
Evaluate the safety of ESIS in pediatric DRE patients. |
Phase II epilepsy surgery testing
|
|
Tolerability -- Quantify study withdrawal and patient/caregiver experience
Periodo de tiempo: during Phase II epilepsy surgery testing
|
Evaluate the tolerability of ESIS in pediatric DRE patients. |
during Phase II epilepsy surgery testing
|
|
Yield -- Rate of induction of habitual seizures
Periodo de tiempo: during Phase II epilepsy surgery testing
|
Evaluate the yield of ESIS in pediatric DRE patients. |
during Phase II epilepsy surgery testing
|
|
Clinical Validity
Periodo de tiempo: during Phase II epilepsy surgery testing and through study completion, an average of 1 year
|
Test the clinical validity of ESIS in pediatric DRE patients by examining the impact of occurance of induced seizures on surgical outcomes. |
during Phase II epilepsy surgery testing and through study completion, an average of 1 year
|
|
Predictors
Periodo de tiempo: during Phase II epilepsy surgery testing
|
Investigate the methodologic, anatomic, and patient-specific predictors of induced seizures in pediatric DRE patients. |
during Phase II epilepsy surgery testing
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Sarah Katie Ihnen, MD, PhD, Children's Hospital Medical Center, Cincinnati
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Neoplasias
- Enfermedades Genéticas Congénitas
- Enfermedades neurodegenerativas
- Anomalías congénitas
- Trastornos Heredodegenerativos, Sistema Nervioso
- Síndromes Neoplásicos Hereditarios
- Síndromes neurocutáneos
- Hamartoma
- Neoplasias Primarias Múltiples
- Malformaciones del Desarrollo Cortical, Grupo I
- Malformaciones del desarrollo cortical
- Malformaciones del Sistema Nervioso
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Epilepsia resistente a los medicamentos
- Esclerosis tuberosa
- Epilepsia
Otros números de identificación del estudio
- 2022-0020
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .